Vivos Therapeutics, Inc. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
Vivos Therapeutics, Inc. (VVOS) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of -$3.99 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-14
- 2026-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -$3.99M.
- 2026-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -$1.27M.
- 2025-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -$1.55M.
- 2025-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $4.58M.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest |
|---|---|
| 2026-06-30 | -$3.99M 10-Q · filed 2026-08-14 |
| 2026-03-31 | -$1.27M 10-Q · filed 2026-08-14 |
| 2025-12-31 | -$1.55M 10-Q · filed 2026-08-14 |
| 2025-06-30 | $4.58M 10-Q · filed 2026-08-14 |
| 2025-03-31 | $4.41M 10-Q · filed 2026-08-14 |
| 2024-12-31 | $7.95M 10-Q · filed 2026-08-14 |
| 2023-12-31 | $411.00K 10-K · filed 2026-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |